Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
Completed
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phase 4
1997-09-26
The purpose of this study is to determine the effectiveness of naltrexone (Revia) or matched
placebo combined with nicotine patch (Nicotrol) or placebo patch using a 2x2 design in
reducing drinking and smoking in patients with both nicotine and alcohol dependence.
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
Completed
The Scripps Research Institute
Phase 4
1997-09-26
The purpose of this study is to determine the effectiveness of naltrexone (Revia) or matched
placebo combined with nicotine patch (Nicotrol) or placebo patch using a 2x2 design in
reducing drinking and smoking in patients with both nicotine and alcohol dependence.
Tobacco Cessation in Postmenopausal Women (Part II) - 2
Completed
National Institute on Drug Abuse (NIDA)
Phase 1
1993-03-01
The purpose of this study is to evaluate the effects of ERT on appetitive behavior and
withdrawal in short-term smoking cessation in postmenopausal females on transdermal nicotine
replacement
Tobacco Cessation in Postmenopausal Women (Part II) - 2
Completed
University of Minnesota
Phase 1
1993-03-01
The purpose of this study is to evaluate the effects of ERT on appetitive behavior and
withdrawal in short-term smoking cessation in postmenopausal females on transdermal nicotine
replacement
Tobacco Cessation in Postmenopausal Women (Part II) - 2
Completed
University of Minnesota - Clinical and Translational Science Institute
Phase 1
1993-03-01
The purpose of this study is to evaluate the effects of ERT on appetitive behavior and
withdrawal in short-term smoking cessation in postmenopausal females on transdermal nicotine
replacement
Nicotine Treatment of Mild Cognitive Impairment (MCI)
Unknown status
National Institute on Aging (NIA)
Phase 1
2003-09-01
The purpose of this 12-month study is to determine whether nicotine, administered in the form
of nicotine patches, can improve symptoms of memory loss in some people experiencing mild
memory problems (referred to in this study as "mild cognitive impairment" or MCI).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
